Frédéric Vanhoutte

Author

Frédéric Vanhoutte

Galapagos (Belgium)

Also Known As

F Vanhoutte, F. Vanhoutte, F.P. Vanhoutte, Frederic Vanhoutte, Frédéric P. Vanhoutte, Frédéric Vanhoutte, Pharm

Publications

1.3K

Citations

H-Index

Concepts

All Affiliations

Galapagos (Belgium)Galapagos (France)Desert Medical Imaging Janssen (Belgium)SGS (Belgium)

About

Frédéric Vanhoutte is an author at Galapagos (Belgium) specializing in medicine, immunology, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	52
2	Immunology	2	2	41
3	Pharmacology	2	2	27
4	Gastroenterology	1	1	16
5	Pathology	1	1	16

Frédéric Vanhoutte

Publications

1.2K

Citations

H-Index

Page 1

	Year	Citations
Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1) René Westhovens, Peter C. Taylor, Rieke Alten, Annals of the Rheumatic Diseases	2016	227
Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2) Arthur Kavanaugh, Joel M. Kremer, L Ponce, Annals of the Rheumatic Diseases	2016	226
Oral liarozole in the treatment of palmoplantar pustular psoriasis: a randomized, double-blind, placebo-controlled study M. Bhushan, A. David Burden, Kathleen McElhone, British Journal of Dermatology	2001	120
Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Filgotinib, a Selective JAK‐1 Inhibitor, After Short‐Term Treatment of Rheumatoid Arthritis: Results of Two Randomized Phase IIa Trials Frédéric Vanhoutte, Minodora Mazur, O.I. Voloshyn, Arthritis & Rheumatology	2017	75
Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of ELX‐02, a Potential Treatment for Genetic Disorders Caused by Nonsense Mutations, in Healthy Volunteers Andi Leubitz, Anat Frydman‐Marom, Neal Sharpe, Clinical Pharmacology in Drug Development	2019	69
Oral liarozole vs. acitretin in the treatment of ichthyosis: a phase II/III multicentre, double-blind, randomized, active-controlled study C.J. Verfaille, Frédéric Vanhoutte, C Blanchet‐Bardon, British Journal of Dermatology	2007	65
A dose escalating phase I study of GLPG0187, a broad spectrum integrin receptor antagonist, in adult patients with progressive high-grade glioma and other advanced solid malignancies Geert A. Cirkel, Bojana Milojkovic Kerklaan, Frédéric Vanhoutte, Investigational New Drugs	2016	60
Safety, pharmacokinetics and pharmacodynamics of GLPG0974, a potent and selective FFA2 antagonist, in healthy male subjects Florence Namour, René Galien, Tim Van Kaem, British Journal of Clinical Pharmacology	2016	53
Pharmacokinetics and Pharmacodynamics of Garetosmab (Anti‐Activin A): Results From a First‐in‐Human Phase 1 Study Frédéric Vanhoutte, Liang Su, Marcella Ruddy, The Journal of Clinical Pharmacology	2020	52
Treatment of psoriasis with oral liarozole: a dose‐ranging study J. Berth‐Jones, George Todd, P.E. Hutchinson, British Journal of Dermatology	2000	39

Page 1